These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 9451905)
1. [Changes in the cytokine concentration during immunotherapy of superficial bladder tumors]. Somogyi L; de Boer EC; de Ruiter GJ; de Reijke TM; Kurth KH; Schamhart DH Orv Hetil; 1998 Jan; 139(2):67-9. PubMed ID: 9451905 [TBL] [Abstract][Full Text] [Related]
2. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941 [TBL] [Abstract][Full Text] [Related]
3. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571 [TBL] [Abstract][Full Text] [Related]
4. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808 [TBL] [Abstract][Full Text] [Related]
5. Oxidative stress of red blood cells during Bacillus Calmette-Guerin intravesical instillations. Mitropoulos D; Deliconstantinos G; Zervas A; Giannopoulos A; Kyriakou G; Dimopoulos C In Vivo; 2000; 14(6):721-4. PubMed ID: 11204488 [TBL] [Abstract][Full Text] [Related]
6. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559 [TBL] [Abstract][Full Text] [Related]
7. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy. Chang SG; Lee SJ; Huh JS; Lee JH Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036 [TBL] [Abstract][Full Text] [Related]
8. Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guérin (BCG) immunotherapy. Basturk B; Yavascaoglu I; Oral B; Göral G; Oktay B Cytokine; 2006 Jul; 35(1-2):1-5. PubMed ID: 16938461 [TBL] [Abstract][Full Text] [Related]
10. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas. Elsässer-Beile U; Gutzeit O; Bauer S; Katzenwadel A; Schultze-Seemann W; Wetterauer U J Urol; 2000 Jan; 163(1):296-9. PubMed ID: 10604379 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831 [TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy of superficial bladder tumors in a hospital department]. Prekopp G; Rosdy E Orv Hetil; 1993 Dec; 134(50):2757-60. PubMed ID: 8265124 [TBL] [Abstract][Full Text] [Related]
13. [Results of BCG immunotherapy in the management of bladder tumors]. Samodai L; Kiss L; Kolozsy Z; Dauda G; Drinóczy M; Mohácsi L Orv Hetil; 1990 Aug; 131(31):1697-702. PubMed ID: 2205825 [TBL] [Abstract][Full Text] [Related]